Budoneb 0.5mg/ml contains budesonide, a corticosteroid most commonly used in inhalation suspension form for the maintenance treatment of asthma and as prophylactic therapy (prevention of asthma symptoms) in children aged 12 months to 8 years[3]. It works by reducing inflammation and swelling in the airways, which helps to improve airflow and makes breathing easier[5].
Budesonide inhalation suspensions, including Budoneb 0.5mg/ml, are typically administered using a nebulizer device. Key uses include:
- Maintenance treatment of asthma: Reduces both daytime and nighttime symptoms and decreases the need for rescue (bronchodilator) medications in children with ongoing asthma[3].
- Anti-inflammatory effects: It helps prevent asthma attacks by reducing airway inflammation, swelling, and irritation[7].
- Improvement of lung function: Demonstrated to improve lung function as measured by increased Forced Expiratory Volume (FEV1) and morning Peak Expiratory Flow (PEF) readings in clinical studies[3].
While its primary and approved use is in pediatric asthma management, budesonide inhalation suspension may also be prescribed off-label or as determined by a healthcare provider for other inflammatory airway conditions[5].
Budesonide, the active compound in Budoneb, is a potent corticosteroid also used in other formulations (capsules, tablets, nasal sprays, rectal foams) to treat various inflammatory diseases such as Crohn’s disease, ulcerative colitis, allergic rhinitis, and eosinophilic esophagitis. However, the 0.5mg/ml suspension form is specifically formulated for inhalation use in asthma[1].
Leave a Reply